Your browser doesn't support javascript.
loading
Investigating sexual health after breast cancer by longitudinal assessment of patient-reported outcomes.
Franzoi, M A; Aupomerol, M; Havas, J; Soldato, D; Lambertini, M; Massarotti, C; Hang, H; Pistilli, B; Fasse, L; Tredan, O; Gillanders, E; Joly, F; Cottu, P; Mouret-Reynier, M-A; Tarpin, C; Arnaud, A; Everhard, S; Martin, A-L; Di Meglio, A; Vaz-Luis, I.
Afiliação
  • Franzoi MA; Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Institute, Villejuif. Electronic address: mariaalice.borinelli-franzoi@gustaveroussy.fr.
  • Aupomerol M; Medical Oncology Department, Gustave Roussy, Villejuif, France.
  • Havas J; Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Institute, Villejuif.
  • Soldato D; Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Institute, Villejuif.
  • Lambertini M; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova; Gynecology Department, Policlinico San Martino, University of Genova, Genova; Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Ge
  • Massarotti C; Physiopatology of Human Reproduction Unit, IRCCS Ospedale Policlinico San Martino, Genova; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal-Child Health (DiNOGMI department), School of Medicine, University of Genova, Genova, Italy.
  • Hang H; Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Institute, Villejuif.
  • Pistilli B; Medical Oncology Department, Gustave Roussy, Villejuif, France.
  • Fasse L; Interdisciplinary and Patient Pathway Department, Institut Gustave Roussy, Villejuif.
  • Tredan O; Centre Léon Bérard, Lyon.
  • Gillanders E; Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Institute, Villejuif.
  • Joly F; Centre François Baclesse, Caen.
  • Cottu P; Institut Curie, Paris.
  • Mouret-Reynier MA; Centre Jean Perrin, Clermont-Ferrand.
  • Tarpin C; Institut Paoli Calmettes, Marseille.
  • Arnaud A; Institut Sainte Catherine.
  • Everhard S; UNICANCER, Paris, France.
  • Martin AL; UNICANCER, Paris, France.
  • Di Meglio A; Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Institute, Villejuif.
  • Vaz-Luis I; Breast Cancer Survivorship Group, INSERM Unit 981, Gustave Roussy Institute, Villejuif.
ESMO Open ; 9(2): 102236, 2024 Feb.
Article em En | MEDLINE | ID: mdl-38350335
ABSTRACT

BACKGROUND:

Sexual concerns are a major unaddressed need among survivors of breast cancer (BC) with significant negative effects on quality of life. We longitudinally analyzed sexual health over time, using patient-reported outcomes.

METHODS:

Patients with stage I-III BC prospectively included from the CANcer TOxicity cohort (CANTO) provided data at diagnosis, then 1, 2, and 4 years afterward. Sexual concerns outcomes included poor body image (score ≤91/100), poor sexual functioning (≤16/100), poor sexual enjoyment (≤66/100), and sexual inactivity (EORTC QLQ-B23). Multivariate generalized estimating equation models assessed associations with sexual concerns after diagnosis, adjusting for age, sociodemographic, tumor, treatment, and clinical characteristics.

RESULTS:

Nearly 78.1% among 7895 patients reported at least one sexual concern between diagnosis and 4 years' follow-up. Over time, the proportion of patients reporting sexual concerns either increased or remained constant with diagnosis. Less than half (46%, range 11.4-57) of the patients with sexual concerns reported the use of supportive care strategies, including gynecological or psychological consultations (range 11.4-57.4). Factors consistently associated with sexual concerns up to 4 years after diagnosis included already reporting the same concern at diagnosis [odds ratio (OR)poor body image 3.48 [95% confidence interval (CI) 3.11-3.89]; ORsexual inactivity 9.94 (95% CI 8.84-11.18), ORpoor sexual function 9.75 (95% CI 8.67-10.95), ORpoorsexual enjoyment 3.96 (95% CI 3.34-4.69)], endocrine therapy use [ORpoor body image 1.15 (95% CI 1.01-1.31); ORsexual inactivity 1.19 (95% CI 1.02-1.39), ORpoor sexual function 1.17 (95% CI 1.01-1.37), ORpoor sexual enjoyment 1.23 (95% CI 1.00-1.53)], and depression [ORpoor body image 2.00 (95% CI 1.72-2.34); ORsexual inactivity 1.66 (95% CI 1.40-1.97), ORpoor sexual function 1.69 (95% CI 1.43-2.00), ORpoor sexual enjoyment 1.94 (95% CI 1.50-2.51)]. Outcome-specific associations were also identified.

CONCLUSIONS:

Sexual concerns seem frequent, persistent, and insufficiently addressed. Pretreatment concerns, endocrine therapy, and emotional distress are commonly associated factors. A proactive evaluation of sexual health across the care continuum is needed, to promptly identify patients suitable for multidisciplinary counseling, referral, and supportive interventions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Saúde Sexual Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: ESMO Open Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Saúde Sexual Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: ESMO Open Ano de publicação: 2024 Tipo de documento: Article